Literature DB >> 28838836

Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study.

Ana Silva Martins1, João André Correia2, Francisco Salvado2, Cecília Caldas2, Nuno Santos2, António Capelo2, Paulo Palmela2.   

Abstract

BACKGROUND: Risk factors for medication-related osteonecrosis of the jaw (MRONJ) are well known, although few studies evaluate the factors that influence treatment outcomes in MRONJ and whether discontinuing antiresorptive medication influences healing.
PURPOSE: (1) Describe the characteristics of a population of patients with MRONJ. (2) Identify the factors associated with favourable outcomes. (3) Identify a temporal correlation between discontinuation of antiresorptives and healing time.
METHODS: A retrospective longitudinal cohort study was carried out, including 77 patients with MRONJ treated between 2004 and 2016. Primary outcome was defined as healed/improved vs. worse/stable. Time to healing was set as the secondary outcome. Statistical significance was defined as p < 0.05.
RESULTS: Primary disease, route of administration, lesion location, and development of complications influenced the outcome of treatment. Significant differences in outcomes according to primary disease (p < 0.05) were found when staging, gender, and lesion location were held constant. Time to healing was longer for patients who discontinued medication more than 3 months after diagnosis than for those who discontinued at diagnosis or before - respectively, 36, 9, and 7 months (p = 0.01).
CONCLUSIONS: The outcome of MRONJ treatment may be influenced by primary disease and route of administration of antiresorptives. Antiresorptive medication discontinuation contributes to reduce healing time in MRONJ.
Copyright © 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bisphosphonates; Denosumab; MRONJ; Osteonecrosis; Sunitinib

Mesh:

Year:  2017        PMID: 28838836     DOI: 10.1016/j.jcms.2017.07.014

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  9 in total

Review 1.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

2.  Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw.

Authors:  Saki Hayashida; Souichi Yanamoto; Shigeyuki Fujita; Takumi Hasegawa; Takahide Komori; Yuka Kojima; Hironori Miyamoto; Yasuyuki Shibuya; Nobuhiro Ueda; Tadaaki Kirita; Hirokazu Nakahara; Mitsuyo Shinohara; Eiji Kondo; Hiroshi Kurita; Masahiro Umeda
Journal:  J Bone Miner Metab       Date:  2019-08-13       Impact factor: 2.626

Review 3.  Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.

Authors:  L Dos Santos Ferreira; L G Abreu; C B Calderipe; M D Martins; L F Schuch; A C U Vasconcelos
Journal:  Osteoporos Int       Date:  2021-07-31       Impact factor: 4.507

Review 4.  Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.

Authors:  Mampei Kawahara; Shinichiro Kuroshima; Takashi Sawase
Journal:  Int J Implant Dent       Date:  2021-05-14

5.  Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice.

Authors:  Terresa Kim; Sol Kim; Minju Song; Cindy Lee; Hideo Yagita; Drake W Williams; Eric C Sung; Christine Hong; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  Am J Pathol       Date:  2018-07-27       Impact factor: 5.770

Review 6.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 7.  Update and review of the gerodontology prospective for 2020's: Linking the interactions of oral (hypo)-functions to health vs. systemic diseases.

Authors:  Yen Chun G Liu; Shou-Jen Lan; Hirohiko Hirano; Li-Min Lin; Kazuhiro Hori; Chia-Shu Lin; Samuel Zwetchkenbaum; Shunsuke Minakuchi; Andy Yen-Tung Teng
Journal:  J Dent Sci       Date:  2020-10-17       Impact factor: 2.080

Review 8.  Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches.

Authors:  Sung-Woon On; Seoung-Won Cho; Soo-Hwan Byun; Byoung-Eun Yang
Journal:  Antioxidants (Basel)       Date:  2021-04-27

9.  Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice.

Authors:  Wen Du; Mengyu Yang; Terresa Kim; Sol Kim; Drake W Williams; Maryam Esmaeili; Christine Hong; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  Int J Oral Sci       Date:  2022-03-21       Impact factor: 6.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.